Condition: Non-Small Cell Lung Cancer · Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to evaluate YL202 monotherapy versus Docetaxel in participants with locally advanced or metastatic non-squamous NSCLC with EGFR mutation who have failed to EGFR-TKI therapy and platinum-based chemotherapy.
This description comes directly from the study's public registry record.
Medilink Study Team · +86 0512-62858368 · clinicaltrials@medilinkthera.com
Always discuss trial participation with your own doctor first.
| Shanghai Dongfang Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Zhejiang Provincial Cancer | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07416994